Change in Antibodies to SARS-CoV-2 Over 60 Days Among Health Care Personnel in Nashville, Tennessee

doi:10.1001/jama.2020.18796

. 2020 Nov 3;324(17):1781-1782.

doi: 10.1001/jama.2020.18796.

Change in Antibodies to SARS-CoV-2 Over 60 Days Among Health Care Personnel in Nashville, Tennessee

Manish M Patel¹, Natalie J Thornburg¹, William B Stubblefield², H Keipp Talbot³, Melissa M Coughlin¹, Leora R Feldstein¹, Wesley H Self²

Affiliations

¹ CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.
² Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
³ Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.

PMID: 32940635
PMCID: PMC7499233
DOI: 10.1001/jama.2020.18796

Change in Antibodies to SARS-CoV-2 Over 60 Days Among Health Care Personnel in Nashville, Tennessee

Manish M Patel et al. JAMA. 2020.

. 2020 Nov 3;324(17):1781-1782.

doi: 10.1001/jama.2020.18796.

Authors

Manish M Patel¹, Natalie J Thornburg¹, William B Stubblefield², H Keipp Talbot³, Melissa M Coughlin¹, Leora R Feldstein¹, Wesley H Self²

Affiliations

¹ CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.
² Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
³ Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.

PMID: 32940635
PMCID: PMC7499233
DOI: 10.1001/jama.2020.18796

Abstract

This study examines the duration of antibody response to SARS-CoV-2 in health care personnel over a 60-day period in Nashville, Tennessee.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Coughlin reported US Patent 7,728,110B2, an isolated human monoclonal antibody that specifically binds to SARS-CoV S protein. No other disclosures were reported.

Figures

See this image and copyright information in PMC

Cited by

Symptom burden, coagulopathy and heart disease after acute SARS-CoV-2 infection in primary practice.
Colleran R, Fitzgerald S, Rai H, McGovern L, Byrne RJ, Mansur A, Cradock A, Lavery R, Bisset J, McKeogh S, Cantwell G, O'Ciardha D, Wilson H, Begossi N, Blake N, Fitzgibbon M, McNulty J, Széplaki G, Heffernan E, Hannan M, O'Donnell JS, Byrne RA. Colleran R, et al. Sci Rep. 2024 Sep 11;14(1):21229. doi: 10.1038/s41598-024-71535-8. Sci Rep. 2024. PMID: 39261512 Free PMC article.
Durability of Cross-Neutralizing Antibodies 5.5 Months After Bivalent Coronavirus Disease 2019 Vaccine Booster.
Rössler A, Knabl L, Netzl A, Bante D, Borena W, von Laer D, Smith DJ, Kimpel J. Rössler A, et al. J Infect Dis. 2024 Mar 14;229(3):644-647. doi: 10.1093/infdis/jiad472. J Infect Dis. 2024. PMID: 38016020 Free PMC article.
SARS-CoV-2 spike antigen-specific B cell and antibody responses in pre-vaccination period COVID-19 convalescent males and females with or without post-covid condition.
Limoges MA, Quenum AJI, Chowdhury MMH, Rexhepi F, Namvarpour M, Akbari SA, Rioux-Perreault C, Nandi M, Lucier JF, Lemaire-Paquette S, Premkumar L, Durocher Y, Cantin A, Lévesque S, Dionne IJ, Menendez A, Ilangumaran S, Allard-Chamard H, Piché A, Ramanathan S. Limoges MA, et al. Front Immunol. 2023 Sep 21;14:1223936. doi: 10.3389/fimmu.2023.1223936. eCollection 2023. Front Immunol. 2023. PMID: 37809081 Free PMC article.
Seroprevalence of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) antibodies among healthcare personnel in the Midwestern United States, September 2020-April 2021.
Bosserman RE, Farnsworth CW, O'Neil CA, Cass C, Park D, Ballman C, Wallace MA, Struttmann E, Stewart H, Arter O, Peacock K, Fraser VJ, Budge PJ, Olsen MA, Burnham CD, Babcock HM, Kwon JH; CDC Prevention Epicenters. Bosserman RE, et al. Antimicrob Steward Healthc Epidemiol. 2023 Aug 4;3(1):e133. doi: 10.1017/ash.2022.375. eCollection 2023. Antimicrob Steward Healthc Epidemiol. 2023. PMID: 37592963 Free PMC article.
Seroprevalence of IgG and IgM Antibodies against SARS-CoV-2 Infection in Inhabitants of Itanagar Capital Region, Arunachal Pradesh, India.
Nobin H, Kothapalli J, Jini M, Chauhan S, Tato Y, Munikumar M. Nobin H, et al. Maedica (Bucur). 2023 Mar;18(1):88-95. doi: 10.26574/maedica.2023.18.1.88. Maedica (Bucur). 2023. PMID: 37266471 Free PMC article.

See all "Cited by" articles

References

1. Ibarrondo FJ, Fulcher JA, Goodman-Meza D, et al. . Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild Covid-19. N Engl J Med. Published online July 21, 2020. doi:10.1056/NEJMc2025179 - DOI - PMC - PubMed
1. Long QX, Tang XJ, Shi QL, et al. . Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020;26(8):1200-1204. doi:10.1038/s41591-020-0965-6 - DOI - PubMed
1. Stubblefield WB, Talbot HK, Feldstein L, et al. ; Influenza Vaccine Effectiveness in the Critically Ill (IVY) Investigators . Seroprevalence of SARS-CoV-2 among frontline healthcare personnel during the first month of caring for COVID-19 patients—Nashville, Tennessee. Clin Infect Dis. 2020;ciaa936. doi:10.1093/cid/ciaa936 - DOI - PMC - PubMed
1. Havers FP, Reed C, Lim T, et al. . Seroprevalence of antibodies to SARS-CoV-2 in 10 sites in the United States, March 23-May 12, 2020. JAMA Intern Med. Published online July 21, 2020. doi:10.1001/jamainternmed.2020.4130 - DOI - PubMed
1. Premkumar L, Segovia-Chumbez B, Jadi R, et al. . The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci Immunol. 2020;5(48):eabc8413. doi:10.1126/sciimmunol.abc8413 - DOI - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

Grants and funding

T32 HL087738/HL/NHLBI NIH HHS/United States

LinkOut - more resources

Full Text Sources
Other Literature Sources
- H1 Connect
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

[1] Ibarrondo FJ, Fulcher JA, Goodman-Meza D, et al. . Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild Covid-19. N Engl J Med. Published online July 21, 2020. doi:10.1056/NEJMc2025179 - DOI - PMC - PubMed

[2] Ibarrondo FJ, Fulcher JA, Goodman-Meza D, et al. . Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild Covid-19. N Engl J Med. Published online July 21, 2020. doi:10.1056/NEJMc2025179 - DOI - PMC - PubMed

[3] Long QX, Tang XJ, Shi QL, et al. . Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020;26(8):1200-1204. doi:10.1038/s41591-020-0965-6 - DOI - PubMed

[4] Long QX, Tang XJ, Shi QL, et al. . Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020;26(8):1200-1204. doi:10.1038/s41591-020-0965-6 - DOI - PubMed

[5] Stubblefield WB, Talbot HK, Feldstein L, et al. ; Influenza Vaccine Effectiveness in the Critically Ill (IVY) Investigators . Seroprevalence of SARS-CoV-2 among frontline healthcare personnel during the first month of caring for COVID-19 patients—Nashville, Tennessee. Clin Infect Dis. 2020;ciaa936. doi:10.1093/cid/ciaa936 - DOI - PMC - PubMed

[6] Stubblefield WB, Talbot HK, Feldstein L, et al. ; Influenza Vaccine Effectiveness in the Critically Ill (IVY) Investigators . Seroprevalence of SARS-CoV-2 among frontline healthcare personnel during the first month of caring for COVID-19 patients—Nashville, Tennessee. Clin Infect Dis. 2020;ciaa936. doi:10.1093/cid/ciaa936 - DOI - PMC - PubMed

[7] Havers FP, Reed C, Lim T, et al. . Seroprevalence of antibodies to SARS-CoV-2 in 10 sites in the United States, March 23-May 12, 2020. JAMA Intern Med. Published online July 21, 2020. doi:10.1001/jamainternmed.2020.4130 - DOI - PubMed

[8] Havers FP, Reed C, Lim T, et al. . Seroprevalence of antibodies to SARS-CoV-2 in 10 sites in the United States, March 23-May 12, 2020. JAMA Intern Med. Published online July 21, 2020. doi:10.1001/jamainternmed.2020.4130 - DOI - PubMed

[9] Premkumar L, Segovia-Chumbez B, Jadi R, et al. . The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci Immunol. 2020;5(48):eabc8413. doi:10.1126/sciimmunol.abc8413 - DOI - PMC - PubMed

[10] Premkumar L, Segovia-Chumbez B, Jadi R, et al. . The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci Immunol. 2020;5(48):eabc8413. doi:10.1126/sciimmunol.abc8413 - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Change in Antibodies to SARS-CoV-2 Over 60 Days Among Health Care Personnel in Nashville, Tennessee

Affiliations

Change in Antibodies to SARS-CoV-2 Over 60 Days Among Health Care Personnel in Nashville, Tennessee

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Miscellaneous